Skip to main content

Table 2 CD14/42b, CD42b MFI1, CD14/HLA-DR and HLADR_MFI Data between the two groups

From: Role of dexmedetomidine in modifying immune paralysis in patients with septic shock: randomized controlled trial

 

Group D (n = 12)

Median (IQR)

Group M (n = 12)

Median (IQR)

P value

ANOVA

P value

CD14/42b 0

14.2 (7–26.9)

6.9 (4.5–14.6)

0.33

0.87

CD14/42b 12

12.6 (4.1–30.9)

14.8 (6.2–19.2)

0.59

 

CD14/42b 24

7 (4–19)

10.25 (6.1–13.2)

0.39

 

CD42b MFI 0

9447.5 (5489.2–13,864)

6874.5 (3403–9161)

0.18

0.15

CD42b MFI 12

7727 (6391–14,584)

7706 (5074–10132)

0.27

 

CD42b MFI 24

9708 (6179–11,072)

7270.5 (4099–8996.7)

0.22

 

CD14/HLADR 0

8 (3.25–20.8)

10 (5.6–11.35)

0.97

0.64

CD14/HLADR 12

8.1 (4.6–15.9)

10.3 (3.9–17.4)

0.99

 

CD14/HLADR 24

12.4 (1.7–19.02)

8 (4.5–13.3)

0.25

 

HLA-DR-MFI 0

1844.5 (1342.5–2615)

1288.5 (844–2008.3)

0.12

0.21

HLA-DR-MFI 12

1316.5 (80.3–2288.3)

1172.5 (1019.3–1879.3)

0.33

 

HLA-DR-MFI 24

1350 (762–2333.3)

1289 (1048.75–1398.5)

0.41

 
  1. Data are presented as the median (interquartile range)
  2. HLA human leukocyte antigen, MFI mean fluorescent intensity